DSIP
ResearchDelta Sleep-Inducing Peptide
- Category
- Sleep & Recovery
- Aliases
- Wagner-Jurgens peptide
- Administration
- Subcutaneous injection (research), Intranasal (research)
Research and regulatory
Development stage
Studied in small human trials since the 1970s-80s for sleep and stress applications; never advanced to FDA approval. In July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed DSIP under the name emideltide for potential addition to the 503A Bulks List and voted against recommending it — the only one of seven reviewed peptides not recommended.
Legal and regulatory
Unscheduled research compound; not FDA approved. Not eligible for 503A compounding — in July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 6-7 against recommending DSIP (reviewed under the name emideltide) for the 503A Bulks List, the only rejection among seven peptides reviewed at that meeting. The FDA has not yet issued a final decision.
Side effects
Not well characterized; generally reported as well-tolerated in older studies